Novel topical ophthalmic formulations for management of glaucoma

Pharmaceutical Research

Volumn 30, Issue 11, 2013, Pages 2818-2831

  Ibrahim, Mohammed M ^a,b   Abd Elgawad, Abd Elgawad H ^b   Soliman, Osama A ^b   Jablonski, Monica M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

brimonidine; cytotoxicity; IOP; nanoparticles; ophthalmic

Indexed keywords

BRIMONIDINE; DICHLOROMETHANE; EYE DROPS; HYDROXYPROPYLMETHYLCELLULOSE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYVINYL ALCOHOL; U 104; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG COATING; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GEL; GLAUCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PH MEASUREMENT; PREFORMULATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SUSTAINED RELEASE FORMULATION; TEMPERATURE; VISCOSITY; ZETA POTENTIAL;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; GLAUCOMA; LACTIC ACID; MICE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; POLYESTERS; POLYGLYCOLIC ACID; QUINOXALINES;

EID: 84886089614     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1109-1     Document Type: Article

References (40)

1. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997;6(4):250-8. PubMed PMID: 9264305. Epub 1997/08/01. eng.
2. Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, et al. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine Nanotechnol Biol Med. 2012;8(5):776-83. PubMed PMID: 21930109. Epub 2011/09/21. eng.
3. Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1335-47. PubMed PMID: 21979886. Pubmed Central PMCID: PMC3225539. Epub 2011/10/08. eng.
4. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1087-101. PubMed PMID: 21879393. Pubmed Central PMCID: PMC3225524. Epub 2011/09/01. eng.
5. Singh KH, Shinde UA. Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Die Pharm. 2011;66(8):594-9. PubMed PMID: 21901982. Epub 2011/09/10. eng.
6. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012;6(9):7595-606. PubMed PMID: 22876910.
7. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80(5):389-93. PubMed PMID: 8695555. Pubmed Central PMCID: PMC505485. Epub 1996/05/01. eng.
8. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Investig Ophthalmol Vis Sci. 1999;40(1):65-73. PubMed PMID: 9888428. Epub 1999/01/15. eng.
9. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797-803. PubMed PMID: 12049586. Epub 2002/06/13. eng.
10. De S, Robinson D. Polymer relationships during preparation of chitosan-alginate and poly-l-lysine-alginate nanospheres. J Control Release Off J Control Release Soc. 2003;89(1):101-12. PubMed PMID: 12695066. Epub 2003/04/16. eng.
11. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55(11):1451-63. PubMed PMID: 14713355. Epub 2004/01/10. eng.
12. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998;17(1):33-58. PubMed PMID: 9537794. Epub 1998/04/16. eng.
13. Smolin G, Okumoto M, Feiler S, Condon D. Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol. 1981;91(2):220-5. PubMed PMID: 7468738. Epub 1981/02/01. eng.
14. Losa C, Calvo P, Castro E, Vila-Jato JL, Alonso MJ. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol. 1991;43(8):548-52. PubMed PMID: 1681069. Epub 1991/08/01. eng.
15. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res. 1993;10(1):80-7. PubMed PMID: 8094245. Epub 1993/01/01. eng.
16. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog Polym Sci. 2007;32(8):762-98.
17. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18. PubMed PMID: 19782542. Epub 2009/09/29. eng.
18. Ibrahim MM, Abd-Elgawad AE, Soliman OA, Jablonski MM. Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release. J Pharm Sci. 2013;102(3):1036-53. PubMed PMID: 23293035.
19. Hong Lu LL, Watson ER, Williams RW, Geisert EE, Jablonski MM, Lu L. Complex interactions of Tyrp1 in the eye. Mol Vis. 2011;17:2455-68.
20. Lu H, Wang XS, Pullen M, Guan HJ, Chen H, Sahu S, et al. Genetic dissection of the Gpnmb network in the eye. Investig Ophthalmol Vis Sci. 2011;52(7):4132-42. PubMed PMID: WOS:000293332500028. English.
21. Swaminathan SLH, Williams R, Lu L, Jablonski MM. Genetic modulation of the iris transillumination defect: a systems genetics analysis using the expanded family of BXD glaucoma strains. Pigment Cell Melanoma Res. 2013.
22. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm. 2006;315(1-2):12-7. PubMed PMID: 16616442. Epub 2006/04/18. eng.
23. Kuzma JW, Bohnenblust SE. Basic statistics for the health sciences. New York: McGraw-Hill Education; 2005.
24. USP29-NF24. "The United States Pharmacopeia" 29th, The National formulary 24th.: United States Pharmacopeial Convention Inc. MD; 2005.
25. Tamizharasi S, Rathi JC, Rathi V. Formulation, and evaluation of pentoxifylline-loaded poly(epsilon-caprolactone) microspheres. Indian J Pharm Sci. 2008;70(3):333-7. PubMed PMID: 20046741. Pubmed Central PMCID: PMC2792523. Epub 2008/05/01. eng.
26. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
27. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23. PubMed PMID: 20524422. Epub 2010/06/09. eng.
28. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337-46. PubMed PMID: 18360646. Pubmed Central PMCID: PMC1936355. Epub 2008/03/25. eng.
29. Kim TH, Jeong YI, Jin SG, Pei J, Jung TY, Moon KS, et al. Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells. Int J Nanomedicine. 2011;6:2621-31. PubMed PMID: 22114493. Pubmed Central PMCID: PMC3218576. Epub 2011/11/25. eng.
30. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release Off J Control Release Soc. 2007;119(1):77-85. PubMed PMID: 17349712. Epub 2007/03/14. eng.
31. Zhou M, Donovan MD. Intranasal mucociliary clearance of putative bioadhesive polymer gels. Int J Pharm. 1996;135(1):;115-25.
32. Wu H, Liu Z, Peng J, Li L, Li N, Li J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm. 2011;410(1-2):31-40. PubMed PMID: 21397671. Epub 2011/03/15. eng.
33. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release Off J Control Release Soc. 2000;69(3):379-88. PubMed PMID: 11102678. Epub 2000/12/05. eng.
34. Hammer ME, Burch TG. Viscous corneal protection by sodium hyaluronate, chondroitin sulfate, and methylcellulose. Investig Ophthalmol Vis Sci. 1984;25(11):1329-32. PubMed PMID: 6436190. Epub 1984/11/01. eng.
35. Huang YY, Chung TW, Tzeng TW. A method using biodegradable polylactides/polyethylene glycol for drug release with reduced initial burst. Int J Pharm. 1999;182(1):93-100. PubMed PMID: 10332078. Epub 1999/05/20. eng.
36. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005;296(1-2):122-32. PubMed PMID: 15885464. Epub 2005/05/12. eng.
37. Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm. 2008;346(1-2):151-9. PubMed PMID: 17681683. Epub 2007/08/08. eng.
38. Leroux JC, Allémann E, De Jaeghere F, Doelker E, Gurny R. Biodegradable nanoparticles - from sustained release formulations to improved site specific drug delivery. J Control Release. 1996;39(2):339-50.
39. German EJ, Hurst MA, Wood D. Reliability of drop size from multi-dose eye drop bottles: is it cause for concern? Eye (London, England). 1999;13(Pt 1):93-100. PubMed PMID: 10396391. Epub 1999/07/09. eng.
40. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm. 2002;238(1-2):77-92. PubMed PMID: 11996812. Epub 2002/05/09. eng.